Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023
05 juin 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., June 05, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of a key abstract at ENDO 2023 taking place June 15-18, 2023, in Chicago, IL. On...
Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
01 juin 2023 08h00 HE
|
Esperion Therapeutics, Inc.
– Submitted four efficacy supplements seeking inclusion of CV risk reduction and expansion of LDL-C lowering – – Anticipated approvals in U.S. in the first half of 2024 – ANN ARBOR,...
Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders
25 mai 2023 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 25, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the 2023 Annual Meeting of Stockholders (the “Annual Meeting”) has been adjourned to allow additional time...
Esperion to Participate in Jefferies Healthcare Conference
24 mai 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 24, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will participate in a fireside chat at the...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
12 mai 2023 16h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 12, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on May 9, 2023, the Company granted 13 new employees 71,500 restricted stock units (RSUs) under...
Esperion Reports First Quarter 2023 Financial Results
09 mai 2023 07h00 HE
|
Esperion Therapeutics, Inc.
– U.S. Net Product Revenue Grew Approximately 27% Y/Y to $17.0 Million – – Retail Prescription Equivalents Grew 15% Y/Y; New to Brand Prescriptions Grew 56% Q/Q – – Strengthened Capital Position...
Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9
04 mai 2023 08h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 04, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that it has retained Gibson Dunn to vindicate its contractual rights against Daiichi Sankyo Europe (“DSE”)...
Esperion to Participate in JMP Securities Life Sciences Conference
01 mai 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., May 01, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will participate in a fireside chat at JMP...
Esperion to Participate in Bank of America Securities 2023 Health Care Conference
27 avr. 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 27, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that Sheldon Koenig, president and chief executive officer, will host a fireside chat at Bank of America...
Esperion to Report First Quarter 2023 Financial Results May 9, 2023
25 avr. 2023 08h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., April 25, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced it will report first quarter 2023 financial results before the open of the U.S. financial markets on...